AACR 2023: Integrated platform enables KRAS-targeted drugs discovery
Discover our end-to-end KRAS services platform presented at AACR 2023! WuXi AppTec scientists have established a comprehensive panel of assays on key mutants of KRAS, including G12C and G12D, to empower KRAS-targeted drug discovery. Our suite of services includes 2D/3D cell proliferation assays (utilizing cell lines harboring single or double KRAS mutations) as well as in vivo models resistant to KRAS G12C inhibitors.
4984_Integrated platform enables KRAS-targeted drugs discovery_final - Copy
Related Content
DNA-encoded libraries have become widely used in drug discovery, and several approaches for linking chemical compounds to DNA have been...
VIEW RESOURCETargeted protein degradation (TPD) technology has become one of the most promising methods to remove specific disease-related proteins using cellular...
VIEW RESOURCE